Re:Macrophage targeting in cancer...BEING FUNDED NOW: Jan 10 Moderna to provide $80mm to private company Carisma...NAVB asks Why then do we not even have an application for FDA Fast Track?
NAVB....Navidea has Fast Track designation on KS ie MAN-DOX. Also because Carisma is private we do not know what they had to give up to get the funds as is seed type money, but what we do know is macrophage science is expanding fast, money is there to fund its expansion and it sure appears Navidea science is complementary and could be more direct/simpler via the TME targeting than ex vivo re engineering then re introduction/injection